Form 8.3 – [ALPHA GROUP INTERNATIONAL PLC – 13 06 2025]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON,…
Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme
English Portuguese June 14, 2025 17:14 ET | Source: Banco Comercial Portugues, S.A. Banco Comercial Portugues, S.A. Please visit: Our Sponsor
Вместо за 50 мин до Бургас за нас “успех” се води за 6 часа.
Отново Гроздан Караджов българският вицепремиер и министър на транспорта вместо за 50 мин до Бургас тържествено се появи със „специален“ влак от цели три вагона, изминал разстоянието от София за…
Form 8.3 – [MARLOWE PLC – 13 06 2025]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE®…
Banco Comercial Português, S.A. informa sobre Relatório intercalar das operações realizadas no âmbito do Programa de Recompra de Ações Próprias
English Portuguese June 14, 2025 17:14 ET | Source: Banco Comercial Portugues, S.A. Banco Comercial Portugues, S.A. Please visit: Our Sponsor
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application…
Robex weiterhin im Plan für erste Goldproduktion bei Kiniero im vierten Quartal 2025
Höhepunkte: Die Bauarbeiten am Kiniero-Goldprojekt von Robex in Guinea verlaufen weiterhin planmäßig und budgetgerecht, so dass die erste Goldförderung für das vierte Quartal 2025 auf Kurs ist.Das Projekt bleibt weiterhin…
Robex reste en bonne voie pour une première coulée d’or à Kiniero au quatrième trimestre 2025
Faits marquants : La construction du projet aurifère Kiniero de Robex, en Guinée, suit le calendrier et le budget prévus. La première coulée d’or est prévue pour le quatrième trimestre…